Evidence map›Paper›PMID 35896583›Full record

ArticleScientific reports2022

SARS-CoV-2 transmission risk screening for safer social events: a non-randomised controlled study.

Rafel Ramos, Lia Alves-Cabratosa, Jordi Blanch, Àlex Pèlach, Laura Albert, Quirze Salomó, Sílvia Cabarrocas, Marc Comas-Cufí, Ruth Martí-Lluch, Anna Ponjoan and 6 more

Abstract readControlled Clinical Trial
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Lessons Learned from In-Person Conferences in the Times of COVID-19.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rafel RamosVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain. rramos.girona.ics@gencat.cat.
Lia Alves-CabratosaVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain.
Jordi BlanchVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain.
Àlex PèlachCentre Blockchain de Catalunya, Parc Científic i Tecnològic de la Universitat de Girona, Girona, Catalonia, Spain.
Laura AlbertCol·legi de Farmacèutics de Girona, Girona, Catalonia, Spain.
Quirze SalomóCentre Blockchain de Catalunya, Parc Científic i Tecnològic de la Universitat de Girona, Girona, Catalonia, Spain.
Sílvia CabarrocasCol·legi de Farmacèutics de Girona, Girona, Catalonia, Spain.
Marc Comas-CufíVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain.
Ruth Martí-LluchVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain.
Anna PonjoanVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain.
Maria Garcia-GilVascular Health Research Group (ISV-Girona), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), c/ Maluquer Salvador, 11 baixos, 17002, Girona, Catalonia, Spain.
Salomé de CambraCentre Blockchain de Catalunya, Parc Científic i Tecnològic de la Universitat de Girona, Girona, Catalonia, Spain.
Albert d'AntaCentre Blockchain de Catalunya, Parc Científic i Tecnològic de la Universitat de Girona, Girona, Catalonia, Spain.
Elisabet BallóDepartment of Medical Sciences, School of Medicine, Campus Salut, Universitat de Girona, Girona, Catalonia, Spain.
Albert AlumUnitat de Qualitat i Seguretat del Pacient, Atenció Primària, Institut Català de la Salut, Girona, Catalonia, Spain.
Rosa Núria AleixandreCol·legi de Farmacèutics de Girona, Girona, Catalonia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an ongoing debate on the implementation of the COVID-19 passport throughout Europe. We sought to build and test a feasible prevention strategy to ensure low SARS-CoV transmission risk in public events. We conducted a non-randomised controlled study. The intervention group obtained a confidential digital certificate of very low capacity for transmitting SARS-CoV-2 and attended socio-cultural events in Girona (Spain) between 1 April and 21 May 2021. The primary care services and a network of pharmacies cooperated in providing the certification. A group of non-attendees was randomly selected from pseudonymised health records as controls. We estimated the incidences of SARS-CoV-2 infection and recorded the challenges in the process. Follow-up was complete for 1351 participants, who were matched with 4050 controls. Mean age of the study population was 31.1 years, and 53% of participants were women. Incidence rates of SARS-CoV infection at 14 days in the group of attendees and non-attendees were 15.9 and 17.7 per 100,000 person-days, respectively; the difference between incidences was - 1.8 (95% CI - 22.8, 19.3). Implementation problems were minor, and 89.2% of respondents to a survey were satisfied with the process. The incidence rate of SARS-CoV-2 infection was not different in the intervention and control groups. These results are in favour of establishing a COVID-19 certificate to attend public events, and connote feasibility of implementation at a population level.

Indexed as

SARS-CoV-2AdultCOVID-19FemaleHumansMaleRisk FactorsSpainTime FactorsTreatment Outcome

Identifiers

PMID35896583
PMCPMC9326423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.